Background: Our innate immunesystem protects us from infections but, since its methods is not all specific for microorganisms, may also induce collateral damage. Severe physical injury often proved deadly throughout evolution. Such injuries may induce massive collateral damage. Nowadays we can initiate advanced critical care for affected patients and save them from imminent trauma-related death. We are therefore faced with the fact that the collateral damage from the immune system may pose a major threat to the patient, the pathophysiology of which is not amenable to direct medical treatment and which leaves us with only passive supportive measures. In this thesis we investigated the role of leucocytes under such circumstances. Our main aim was to understand better the role of leucocytes in the development of increased vascular permeability after burns and trauma. More specifically we investigated the impact of an injury on the function of leucocytes such as the dynamic change of certain cell-surface receptors on the leucocytes and in their numbers and immature forms. We wanted to find out if the increased pulmonary vascular permeability after a burn could be mediated through heparin binding protein (HBP) released from granuloctes, and whether HBP could be used as a biomarker for respiratory failure after trauma. We also wanted to confirm the possible role of histamine as a mediator of the systemic increase in vascular permeability after burns. Methods: The dynamic change of cell-surface receptors was measured by flow-acquired cytometer scanning (FACS) on blood samples taken after burns. The concentrations of HBP after a burn and mechanical trauma were analysed in plasma. Pulmonary vascular permeability after a burn was assessed using transpulmonary thermodilution. The histamine turnover after a burn was assessed with high performance liquid chromatography (HPLC) for concentrations of histamine and methylhistamine in urine. Results: We confirmed earlier investigations showing altered expression of receptors on leucocytes after a burn, receptors intimately associated with leucocyte functions (study I). In a pilot study of 10 patients we measured plasma concentrations of HBP and found them to be increased soon after a burn (study II). This finding was not confirmed in a larger, more extensive and specific study of 20 patients. We did, however, find an association between alterations in the number of leucocytes soon after a burn and pulmonary vascular permeability, indicating that they had a role in this process (study III). In another study of trauma (non burn) we found an association between the concentration of HBP in early plasma-samples after injury and the development of ARDS, indicating that granulocytes and HBP have a role in its aetiology (study IV). We found a small increase in urinary histamine and normal urinary methylhistamine concentrations but had anticipated a distinct increase followed by a decrease after reading the current papers on the subject. This indicates that the role of histamine as a mediator of increased vascular permeability after burns may have been exaggerated (study V). Conclusions: We conclude that leucocytes are affected by burns and trauma, and it is likely that they contribute to the development of respiratory failure and acute respiratory distress syndrome (ARDS). HBP is a candidate biomarker for the early detection of ARDS after trauma, and the white blood count (WBC) is a useful biomarker for the detection of decreased oxygenation soon after a burn.

Nous avons identifié l’expression du récepteur des angiopoïétines, le récepteur Tie2, à la surface des neutrophiles humains. De plus, nous avons démontré qu’Ang1 et Ang2 induisent des activités pro-inflammatoires sur les neutrophiles, comme l’adhésion aux cellules endothéliales (CEs) et la synthèse du facteur d’activation plaquettaire (PAF). Puisque le PAF augmente la viabilité des neutrophiles et que les angiopoïétines modulent la survie des CEs, nous avons voulu évaluer l’effet des angiopoïétines sur la survie des neutrophiles. Des neutrophiles humains ont été isolés à partir du sang de donneurs sains en accord avec le comité d’éthique de l’Institut de cardiologie de Montréal. La viabilité des neutrophiles a été mesurée par cytométrie en flux à l’aide de marqueurs d’apoptose et de nécrose. Un traitement avec des témoins positifs, soit l’interleukine 8 (IL-8; 25 nM) ou le PAF (100 nM), a augmenté la survie basale des neutrophiles de 34 et 27%, respectivement. De plus, un traitement avec Ang1 (1 pM – 10 nM) a augmenté la survie des neutrophiles jusqu’à 35%, alors qu’Ang2 n’a eu aucun effet. La combinaison de l’IL-8 ou du PAF avec Ang1 (10 nM) a eu un effet additif sur la viabilité des neutrophiles et a augmenté la survie de 56 et 60%, respectivement. Un prétraitement avec des anticorps bloquants contre l’IL-8 a permis d’inhiber l’activité anti-apoptotique de l’IL-8 et d’Ang1 de 92 et 80%, respectivement. Ainsi, notre étude est la première à démontrer la capacité d’Ang1 à prolonger la viabilité des neutrophiles, qui est principalement causée par la relâche d’IL-8. / We reported the expression of angiopoietin receptor Tie2 on the surface of human neutrophils. In addition, we reported that Ang1 and Ang2 are both capable to promote pro-inflammatory activities in neutrophils, namely their adhesion onto endothelial cells (ECs) and platelet-activating factor (PAF) synthesis. PAF is known to promote pro-survival activity on neutrophils and since both angiopoietins can modulate ECs viability, we addressed whether Ang1 and/or Ang2 could modulate neutrophil viability. Human neutrophils were isolated from blood of healthy volunteers in accordance with the guidelines of the Montreal Heart Institute’s ethical committee. Neutrophil viability was assessed by flow cytometry using apoptotic and necrotic markers. Treatment with anti-apoptotic mediators such as interleukin 8 (IL-8; 25 nM) and PAF (100 nM) increased neutrophil basal viability by 34 and 27%, respectively. In addition, treatment with Ang1 (1 pM – 10 nM) increased neutrophil viability by up to 35%, while Ang2 had no effect. Combination of IL-8 or PAF with Ang1 (10 nM) provided an additive effect on neutrophil viability and further increased viability by 56 and 60%, respectively. Pretreatment of the neutrophils with blocking anti-IL-8 antibodies inhibited the anti-apoptotic effect of IL-8 and Ang1 by 92 and 80%, respectively. In summary, our data are the first one to report Ang1 pro-survival activity on neutrophils, which is mainly driven through IL-8 release.

Les polynucléaires neutrophiles (PN) sont des cellules essentielles au cours de la réponse immunitaire innée ; recrutés rapidement au site inflammatoire où ils participent à la phase aigüe, ils vont aussi contribuer à la résolution de l'inflammation. Ils peuvent en effet moduler la réponse adaptative par interaction avec les lymphocytes (Ly) ou les cellules dendritiques (DC) via des médiateurs solubles ou des interactions cellulaires directes. Les Neutrophil Extracellular Traps (NETs) libérés par les PN activés pourraient jouer un rôle important dans ce contexte. Les NETs sont des filaments de chromatine décondensée associés à des protéines issues principalement des granulations et du cytoplasme. Ils sont essentiels dans la réponse anti-infectieuse mais semblent également impliqués dans la physiopathologie de certaines maladies auto-immunes et inflammatoires. L'objectif de ce travail a été d'évaluer les effets des NETs sur la maturation des DC dans un contexte inflammatoire au cours duquel les PN et les DC peuvent co-exister, assurant ainsi un pont entre immunité innée et immunité adaptative. La première partie de ce travail a consisté à développer un modèle de production, isolement et caractérisation des NETs issus de PN sanguins humains. L'ionophore de calcium A23187 a été choisi pour induire les NETs et l'enzyme de restriction AluI a permis la récupération de fragments de NETs de taille hétérogène. Certains des composants de ces NETs sont quantifiables (ADN, élastase, histone 3 en particulier), et nous avons montré qu'ils conservaient leurs capacités bactéricides in vitro. Ces échantillons de NETs constituent donc un outil biologique standardisé, permettant d'évaluer leurs effets sur des cellules ou des tissus. Dans la deuxième partie de ce travail, nous avons mis en évidence que ces NETs purifiés régulaient négativement la maturation de moDC induites par le LPS (expression de HLA-DR, CD80, CD83, CD86 et production de TNFα, IL-12, IL-6, IL-23). De plus, les NETs diminuent la capacité de ces moDC à induire la prolifération des LyT, et leur polarisation est modulée en favorisant la production de cytokines de type Th2 (IL-5 et IL-13) aux dépens de cytokines de types Th1 (INFγ) et Th17 (IL-17). De manière intéressante, la capacité de migration des moDC activées par le LPS n'est pas modifiée en présence de NETs. En résumé, ces résultats suggèrent que les NETs pourraient jouer un rôle immunorégulateur sur la maturation des moDC dans des conditions inflammatoires. Les NETs produits par les PN activés pourraient ainsi participer à la régulation indispensable de la réponse inflammatoire.

Hantaviruses are the causative agents of hemorrhagic fever with renal syndrome (HFRS) in Eurasia, and of hantavirus cardiopulmonary syndrome (HCPS) in the Americas. Transmission to humans usually occurs by inhalation of aerosolized virus-contaminated rodent excreta. To date, human-to-human transmission has only been described for the Andes hantavirus. The mode of transmission of Andes hantavirus is not yet known, but transmission through saliva has been suggested. In Sweden, we have one hantavirus that is pathogenic to humans, Puumala virus (PUUV), which is endemic in Central and Northern Europe. It induces a relatively mild form of HFRS, also called nephropathia epidemica (NE). The rodent reservoir is the bank vole (Myodes glareolus). The mechanism behind the pathogenesis of hantavirus is complex and probably involves both virus-mediated and host-mediated mechanisms. The aim of this project was to investigate the transmission mechanisms and pathogenesis of hantavirus disease in humans. In our first study, we described the largest outbreak of PUUV so far in Sweden. We investigated factors that might be important for causing the outbreak, and suggested that a peak in the bank vole population together with concurrent extreme weather conditions most probably contributed to the outbreak. Our next studies concentrated on human-to-human transmission of hantaviruses. We found PUUV RNA in saliva from PUUV-infected patients, suggesting that there is PUUV in the saliva of infected humans, although no person-to person transmission appears to occur with PUUV.  In the studies that followed, we showed that human saliva and human salivary components could inhibit hantavirus replication. We also found PUUV-specific IgA in the saliva of PUUV-infected patients, which might prevent person-to-person transmission of the virus.  In the final study, we focused on the pathogenesis of NE. One hundred five patients were included in a prospective study.  They were divided into a group with mild disease and a group with moderate or severe disease. We found that the immune response had a dual role in disease development. It was partly responsible for development of severe disease, with significantly higher amounts of neutrophils in severely ill patients, but it was also protective against severe disease, because patients with mild disease had higher levels of PUUV-specific IgG. In conclusion, a peak in the bank vole population in combination with extreme weather will increase the risk of human infection, PUUV RNA is present in saliva, PUUV-specific IgA and salivary components inhibit person-to-person transmission of PUUV, and the immune response is important for the pathogenesis of PUUV and the severity of the disease. / Hantavirus är en grupp av virus som finns hos gnagare som bär på viruset utan att själva bli märkbart sjuka. Varje hantavirus har anpassat sig till sin egen art av gnagare som de infekterar (kallas virusets reservoar). Hantaviruset kan överföras till människor från gnagare och kallas då för en zoonos eftersom detsprids från djur till människa. I människa orsakar hantavirus blödarfeber med njurpåverkan i Eurasien och blödarfeber med med hjärt och lungpåverkan i Nord- och Sydamerika. I Sverige har vi bara ett hantavirus som är sjukdomsframkallande hos människor, Puumala-viruset som även finns i delar av övriga Europa. Det framkallar en relativt mild form av blödarfeber, som kallas sorkfeber eller Nephropathia epidemica. Puumala-virusets reservoar är skogssorken (Myodes glareolus). Människor smittas oftast av hantavirus när de andas in infekterat damm som innehåller utsöndringar (avföring, urin eller saliv) från gnagare som har torkat in och sedan blivit luftburet. Vad man vet hittills så finns det bara ett hantavirus som smittar från person till person, för övriga hantavirus är människan en ”dead end”. Det virus som kan smitta från person till person heter Andes hantavirus och finns i Sydamerika. Andes hantavirus har en mus som reservoar från vilken människor kan smittas, sedan har smittan i vissa fall förts vidare från människa till människa, som tur är har dessa utbrott gått att stoppa. Fastän utbrotten har varit små har många personer dött, eftersom dödligheten är så hög, ungefär 30-40% av de diagnostiserade fallen dör. Hur Andes hantavirus överförs från människa till människa är inte känt men överföring genom saliv har föreslagits. Hur viruset ger upphov till sjukdom hos människa är inte klarlagt. Studier talar för att mekanismen bakom sjukdomsutvecklingen (den så kallade patogenesen) hos hantavirusorsakade blödarfebrar är komplex. Sannolikt beror patogenesen både på egenskaper hos viruset och värden d.v.s. människan som är smittad av viruset. Vårt mål med detta projekt var att undersöka vad som hindrar överföring av Puumala hantavirus från människa till människa och att undersöka hur virusinfektionen påverkar sjukdomsutvecklingen hos människan. I vår första studie beskrev vi det största utbrottet av sorkfeber hittills i Sverige och vi undersökte faktorer som kan ha orsakat utbrottet. Vi föreslog att en topp i skogssorkpopulationen samtidigt med extremt varmt väder troligen bidrog till utbrottet. Utbrottet skedde i december och det extremt varma vädret medförde att snön smälte bort. Sorkarna bor vanligtvis under snön på vintern, vi tror att frånvaro av snötäcke fick sorkarna att söka sig till byggnader för att söka skydd och där kom i kontakt med människor. Våra efterföljande studier fokuserade på överföring av hantavirus från människa till människa. Vi hittade Puumala-virusets arvsmassa (RNA) i saliv från sorkfeberpatienter, vilket tyder på att det finns Puumala-virus i saliven hos infekterade människor, även om ingen överföring från person till person verkar inträffa. I efterföljande studier visade vi att mänsklig saliv och mänskliga salivkomponenter minskar hantavirus smittsamhet. Vi fann också Puumala-virusspecifika IgA-antikroppar i saliven från sorkfeberpatienter, vilket kan förhindra överföring från person till person. I den sista studien fokuserade vi på patogenesen hos människor efter hantavirusinfektion. 105 patienter ingick i en prospektiv studie och delades in i en grupp med mild sjukdom och en grupp med måttlig/svår sjukdom. Vi hittade en dubbel roll hos immunsvaret för sjukdomsutvecklingen. Immunsvaret var delvis ansvarig för utveckling av svår sjukdom med betydligt högre mängd neutrofiler hos svårt sjuka patienter, men det var också skyddande mot allvarlig sjukdom, eftersom patienter med en mild sjukdom hade högre nivåer av Puumalavirusspecifika IgG-antikroppar. Detta talar för att behandling med IgG-antikroppar specifikt riktade mot hantavirus skulle kunna vara effektiv hos hantavirusinfekterade patienter. Sammanfattningsvis; en topp i skogssorkspopulationen i kombination med extremt väder ökar risken för infektion hos människor; Puumala-virus arvsmassa (RNA) finns i saliv; Puumala-virusspecifika IgA-antikroppar och salivkomponenter hämmar överföring av Puumalavirus från person till person; immunsvaret är viktigt för Puumala-virus patogenes och sjukdomens svårighetsgrad.

Incidences of uterine infections in dairy cattle are high between parturition and Day 21 postpartum. Dairy cows with uterine infections are at risk for prolonged periods of days open and multiple services before becoming pregnant. Neutrophils are the first wave of immune system defense against uterine contamination. Neutrophil function seems to be mediated by reproductive hormones and good uterine health is related to properly functioning neutrophils. To elucidate the interaction between reproductive hormones, neutrophils and uterine health in dairy cows the objectives of this research were to evaluate: 1) changes in circulating white blood cell populations during the estrous cycle, 2) the effects of prostaglandin F₂[subscript α](PGF₂[subscript α]) on circulating white blood cell populations and 3) the effects of a two-injection PGF₂[subscript α] regimen on uterine neutrophil and bacterial populations and numbers of days open and services per conception. In the first experiment, the effect of stage of the estrous cycle on plasma neutrophil numbers was evaluated. Neutrophils were observed throughout the entire estrous cycle and numbers were greatest (P<0.05) on Day 14 (mid-cycle), when the corpus luteum was the dominant ovarian structure and plasma progesterone was at its acme. In the second experiment, plasma neutrophil numbers were examined in cows after injections of saline or the PGF₂[subscript α] pharmaceutical product, Lutalyse. Compared to saline, numbers of neutrophils were greater (P<0.05) 4 and 8 hr after Lutalyse injection. In the third experiment, neutrophil numbers were examined after injections of saline, Lutalyse or the PGF₂[subscript α] analog, Estrumate. Compared to saline, numbers of neutrophils did not differ (P>0.10) from cows injected with Lutalyse or Estrumate. In the fourth experiment, uterine bacterial populations and numbers of neutrophils were quantified in cows treated with Lutalyse or saline on Days 0 and 14 or 14 and 28 postpartum. Compared to saline, Lutalyse treatment decreased (P<0.05) total bacteria present in the uterus and increased (P<0.05) the number of uterine neutrophils. In experiment five, numbers of days open and services per conception were evaluated in cows treated with Lutalyse or saline on Days 0 and 14 or 14 and 28 postpartum. Compared to saline, Lutalyse decreased days open (154.7 ± 14.1 vs. 120.1 ± 7.9 days, respectively; P<0.05) and services per conception (3.0 ± 0.4 vs. 2.3 ± 0.2 services, respectively; P=0.09). These results suggest PGF₂[subscript α] treatment can increase neutrophil and depress bacterial cell populations in favor of the dairy cow's uterine health and may explain why fertility is improved when PGF₂α is administered early in the postpartum period. / Graduation date: 2012

Le TRALI représente un œdème pulmonaire lésionnel aigu survenant au cours d’une transfusion. Son mécanisme étiopathologique encore très imprécis conduit aujourd’hui à une sous-estimation de son incidence. Des études clinico-anatomiques ont souligné le rôle central des polynucléaires neutrophiles (PMN) en montrant que le TRALI résulte de l’accumulation de PMN au contact de l’endothélium lésé des capillaires pulmonaires. De nombreux investigateurs ont tenté de définir le facteur déclenchant présent dans le produit sanguin transfusé et évoquèrent l’existence d’un conflit immunologique par infusion d’anticorps anti-HLA. En appui avec les données de la littérature, ce travail a pour but d’apporter une meilleure connaissance du mécanisme du TRALI afin d’en améliorer son diagnostic, sa prévention et la prise en charge du patient. Tout d’abord, nous confirmons l’implication des anticorps anti-HLA dans la survenue du TRALI en validant pour la première fois l’hypothèse du modèle en deux étapes: une première étape préalable est requise chez le patient présentant une situation clinique ou thérapeutique prédisposante qui aboutit à une pré-stimulation des PMN, puis une seconde étape, dépendante de l’apport d’anticorps anti-HLA lors de la transfusion, entraîne l’activation de la NADPH oxydase phagocytaire. Cela conduit à l’activation des PMN et la libération de dérivés réactifs de l’oxygène qui sont directement responsables de la lésion endothéliale pulmonaire et provoque une augmentation de la perméabilité endothéliale. Nous démontrons en plus l’existence d’un seuil d’anticorps anti-HLA nécessaire pour déclencher une forte activation des PMN. Enfin, nous avons mis en évidence un mécanisme d’activation des PMN par les anticorps anti-HLA faisant intervenir la formation de complexes immuns antigène – anticorps à la surface des PMN. Ces complexes immuns sont reconnus avec une affinité plus grande que les anticorps seuls par les récepteurs Fc des PMN. Cette double interaction au sein d’un même PMN pourrait favoriser la formation de cluster de récepteurs Fc activés au niveau de radeaux lipidiques, ce qui induirait une activation optimisée de ces récepteurs, entraînant une cascade de signalisation aboutissant à l’activation de la NADPH oxydase des PMN. Nos résultats constituent un rationnel scientifique solide pour accéder à une meilleure connaissance du TRALI. / TRALI represents an acute non-cardiogenic pulmonary oedema following blood transfusion. The unknown etiopathological mechanism of TRALI leads to an underestimation of the incidence. Clinical and anatomical studies highlighted the major role of neutrophils (PMN) and showed that TRALI results from an increased number of neutrophils within the pulmonary capillary endothelium. Many evidence suggest that antibodies recognizing human leukocyte antigens (HLA) present in the blood transfusion are the predominant trigger leading to TRALI. Towards theses findings, we investigated the precise mechanism in TRALI in order to get a better knowledge of its diagnosis, its prevention and the patient care. We confirm the major role of anti-HLA antibodies and validate for the first time the two-hit model: the first-hit related to the patient clinical condition leads to their PMN stimulation, followed in the second-hit by the infusion of blood products containing anti-HLA antibodies that activate the phagocytic NADPH oxidase. This event induces PMN activation and the release of reactive oxygen species that are directly responsible for the pulmonary endothelial damage and cause the endothelial permeability increase. We also demonstrate the cut-off of anti-HLA antibodies that raises PMN activation. Finally, we showed that both the antigen-binding and the Fc-binding systems to antibodies are needed to induce a major PMN activation. We found that the binding of anti-HLA antibodies to HLA antigens promote the formation of cluster of Fc receptors within lipid rafts. The translocation of Fc receptors into lipid rafts improve Fc receptors activation, leading to intracellular signal transduction and activation of effector functions, such as NADPH oxidase activation and release of reactive oxygen species involved in tissue damage.

Background e objetivo. A reconstituição celular hematopoiética com o transplante de células tronco hematopoiéticas (TCTH) alogênicas é um método de tratamento estabelecido para uma variedade de doenças hematológicas, oncológicas e imunológicas. Entretanto, TCTH está associado a considerável morbimortalidade devido a fatores como recidiva da doença de base, grau de compatibilidade HLA, tipo de regime de condicionamento e infecções durante o período de neutropenia. Este estudo investigou a associação entre o aloantígenoneutrofílico humano (HNA) e o dia de pega, a ocorrência de DECH aguda e TRM em pacientes que foram submetidos a transplante de células tronco hematopoiéticas alogênico. Tipo de estudo e local. Estudo de coorte prospectivo realizado no Hospital de Clínicas de Porto Alegre. Métodos. Avaliamos 27 pacientes transplantados entre maio de 2013 e abril de 2014 e seus respectivos doadores. A tipagem HNA foi realizada, nas amostras dos doadores, por PCR-SSP e os anticorpos anti-HNA foram detectados nos pacientes utilizando o kit LABSCREEN MULTI (LSMUTR – One Lambda). Resultados. A idade variou entre 1 a 63 anos, com uma média de 20,4 ± 17,5 anos. Dezenove pacientes eram pediátricos (<21 anos) com média de idade de 10,05 ± 6,4 anos e entre os pacientes adultos a média foi 42,2 ± 12,6 anos. Houve um discreto predomínio do sexo masculino 16 (59,3%). As leucemias agudas foram frequentes em 19 (70,4%) dos pacientes, outras doenças oncohematológicas malignas (Linfoma Hodgkin e Linfoma não Hodgkin) estiveram em 3 (11,1%) e as não malignas (síndrome mielodisplásica, osteopetrose, hemoglobinúria paroxicística noturna, aplasia e doença granulomatosa) estiveram em 6 (22,2%) dos casos. A maioria dos pacientes 19 (70,4%), apresentavam a doença há menos de 12 meses na época do transplante e 24 (88,9%) deles foram totalmente compatível com seus doadores quanto ao sistema HLA. O regime de condicionamento mieloablativo foi utilizado em 16 (59,2%) dos pacientes e a profilaxia padrão para DECH (ciclosporina e metotrexate) foi utilizada em 15 (55,5%) dos pacientes. O dia de pega teve uma mediana de 19 e mínimo e máximo de 15 e 30, respectivamente. Quatro pacientes (14,8%) tiveram óbito antes da pega. Aproximadamente 63% (17 pacientes) apresentaram DECH aguda (em todos os estágios) e a taxa de mortalidade (TRM) foi de aproximadamente 44% dos casos (12 pacientes). Os pacientes que receberam TCTH de um doador aparentado tiveram TRM de aproximadamente 41% (7 pacientes) e os que receberam de um doador não aparentado foi de aproximadamente 45% (5 pacientes). A frequência dos antígenos HNA detectados nos doadores foi de 46,4% HNA-1a, 89,3% HNA-1b, 3,6% HNA-1c, 96,4% HNA-3a, 32,1% HNA-3b, 96,4% HNA-4a, 21,4% HNA-4b, 85,7% HNA-5a e 71,4% HNA-5b. A frequência dos anticorpos anti-HNA1a, anti-HNA1b, anti-HNA1c e anti-HNA2 no D0 foram respectivamente 46,4%, 42,9%, 42,9% e 53,6%. A associação entre a tipagem HNA dos doadores e anticorpos anti-HNAdos receptores com dia da pega, DECH aguda e TRM não mostrou correlação estatisticamente significativa. Conclusão. A frequência de HNA encontradanos doadores está de acordo com o descrito pela literatura. Contudo, a frequência dos anticorpos anti-HNAs foi bastante alta na população do estudo, embora a maioria apresentasse doença há menos de 12 meses até o transplante. Apesar de não encontrarmos uma correlação, novos estudos são necessários para melhor avaliar o papel do HNA no desfecho do TCTH. / Background and purpose. Hematopoietic cellular reconstruction with allogeneic hematopoietic stem cell transplantation (HSCT) is an established method of treatment for a variety of hematological, oncologic and immunologic diseases. However, HSCT is associated with considerable morbidity and mortality due to recurrence of underlying disease, incomplete HLA compatibility, type of conditioning regimen and infection during the unavoidable period of neutropenia. This study investigates a surrogate cause of morbidity: compatibility of Human Neutrophil Antigens (HNA) between donors and receivers and its association with day of engraftment, incidence of acute graft versus host disease (GVHD) and total rate of mortality (TRM) in patients who underwent allogeneic HSCT. Type of study and location. Prospective cohort study carried out at the Hospital de Clínicas de Porto Alegre (HCPA), Brazil. Methods. We have studied 27 patients who underwent HSCT between May, 2013 and April, 2014, and their respective donors. HNA typing in the donors was performed by PCR-SSP (One Lambda) and anti-HNA antibodies in receivers were detected using the LABSCREEN MULTI kit (LSMUTR-One Lambda). Results. The age ranged from 1 to 63 years, with an average of 20.4 ± 17.5 years. Nineteen were pediatric patients (<21 years) with an average age of 10.05 ± 6.4 years, and among adult patients the average was 42.2 ± 12.6 years. There was a discreet male prevalence, 16 (59,3%). The acute leukemias were frequent in 19 (70,3%) of patients, other malignant onco-hematological diseases (Hodgkin Lymphoma and non-Hodgkin's Lymphoma) in 3 (11,1%) and non-malignant (myelodysplastic syndrome, osteopetrosis, paroxysmal nocturnal hemoglobinuria, aplasia and granulomatous disease) in 6 (22,2%). Nineteen (70,3%) of the patients, had the disease for less than 12 months at the time of the transplant and 24 (88,9%) were fully HLA compatible with their donors. Myeloablative conditioning regimen was used in 16 (59,3%) of the patients and the standard prophylaxis for GVHD (cyclosporine and methotrexate) was used in 15 (55,5%) of the patients. The day of engraftment had a median of 19 and minimum and maximum of 15 and 30, respectively. Four patients (14,8%) died before the engraftment. Approximately 17 patients (63%) showed acute GVHD (in all stages) and the total rate of mortality (TRM) was approximately 44% of the cases (12 patients). Patients who received HSCT from a related donor had TRM of approximately 41% (7 patients) and those who have received an unrelated donor was approximately 45% (5 patients). The frequency of HNA antigens detected in donors was 46,4% HNA-1a, 89,3% HNA-1b, 3,6% HNA-1c, 96,4% HNA-3a, 32,1% HNA-3b, 96,4% HNA-4a, 21,4% HNA-4b, 85,7% HNA-5a and 71,4% HNA-5b. The frequency of antibodies anti-HNA1a, anti-HNA1b, anti-HNA1c and anti-HNA2 at D0 were respectively 46,4%, 42,9%, 42,9% and 53,6%. The association between the HNA donor typing and anti-HNA antibodies of receivers with day of the engraftment, acute GVHD and TRM showed no statistically significant correlation. Conclusion. The HNA frequency found in our donors was close to the described in the literature. The frequency of anti-HNAs antibodies, however, was quite high in our study population; although the majority presented the disease for less than 12 months before the transplant. The association between HNA donor typing and anti-HNA antibodies of patients with day of engraftment, acute GVHD incidence and TRM showed no statistically significant correlation. As the number of cases was small, further studies with higher numbers and with antigen/antibodies assayed in both sides of transplantation pairs, are needed to better assess the role of the HNAs on the outcome of HSCT.

Made available in DSpace on 2014-12-17T14:03:33Z (GMT). No. of bitstreams: 1 JannisonKCR_DISSERT.pdf: 3798069 bytes, checksum: 8a7cf649e9d79113b8221c30286c11d0 (MD5) Previous issue date: 2010-05-07 / Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico / Seeds from legumes including the Glycine max are known to be a rich source of protease inhibitors. The soybean Kunitz trypsin inhibitor (SKTI) has been well characterised and has been found to exhibit many biological activities. However its effects on inflammatory diseases have not been studied to date. In this study, SKTI was purified from a commercial soy fraction, enriched with this inhibitor, using anion exchange chromatography Resource Q column. The purified protein was able to inhibit human neutrophil elastase (HNE) and bovine trypsin. . Purified SKTI inhibited HNE with an IC50 value of 8 ?g (0.3 nM). At this concentration SKTI showed neither cytotoxic nor haemolytic effects on human blood cell populations. SKTI showed no deleterious effects on organs, blood cells or the hepatic enzymes alanine amine transferase (ALT) and aspartate amino transferase (AST) in mice model of acute systemic toxicity. Human neutrophils incubated with SKTI released less HNE than control neutrophils when stimulated with PAF or fMLP (83.1% and 70% respectively). These results showed that SKTI affected both pathways of elastase release by PAF and fMLP stimuli, suggesting that SKTI is an antagonist of PAF/fMLP receptors. In an in vivo mouse model of acute lung injury, induced by LPS from E. coli, SKTI significantly suppressed the inflammatory effects caused by elastase in a dose dependent manner. Histological sections stained by hematoxylin/eosin confirmed this reduction in inflammation process. These results showed that SKTI could be used as a potential pharmacological agent for the therapy of many inflammatory diseases / Sementes de leguminosas s?o conhecidas como uma rica fonte de inibidores de proteinases, destacando-se dentre estes o inibidor de tripsina da soja (SKTI) que ? uma prote?na amplamente estudada e caracterizada para muitas propriedades biol?gicas. Entretanto seus efeitos aplicados a desordens inflamat?rias ainda s?o pouco conhecidos. SKTI foi purificado ? partir de uma fra??o comercial de soja atrav?s de cromatografia de troca ani?nica em Resource Q. A prote?na purificada foi capaz de inibir a elastase de neutr?filos humanos (ENH) e a tripsina bovina. O valor da sua IC50 foi de 8 &#956;g.mL-1 (0.3 nM) e nessa concentra??o o SKTI n?o foi capaz de provocar efeitos hemol?ticos ou citot?xicos sobre as popula??es celulares sangu?neas humanas. Por meio do modelo de toxicidade sist?mica aguda, utilizando camundongos, tamb?m n?o foram observados efeitos delet?rios sobre ?rg?os, c?lulas sangu?neas e altera??es nos n?veis das enzimas hep?ticas aspartato amino transferase (AST) e alanina amino transferase (ALT). Neutr?filos humanos incubados com SKTI na concentra??o de 0.3 nM apresentaram uma diminui??o da libera??o de ENH quando estimulados pelos ativadores PAF e fMLP (83,1% e 70 %, respectivamente). Estes resultados mostram que o SKTI foi capaz de afetar ambas as vias PAF/fMLP de libera??o de ENH, sugerindo esta prote?na como um poss?vel antagonista dos receptores PAF/fMLP. Modelos in vivo de inj?ria pulmonar aguda mediante estimula??o por LPS de Escherichia. coli demonstraram uma supress?o significativa dos eventos inflamat?rios atribu?dos ? atividade elast?sica de forma dose dependente. Cortes histol?gicos corados por hematoxilina e eosina confirmaram a diminui??o da inflama??o tecidual. Estes resultados sugerem que o SKTI pode ser indicado como um potencial agente farmacol?gico na terapia de muitas doen?as inflamat?rias

Made available in DSpace on 2014-12-17T14:03:37Z (GMT). No. of bitstreams: 1 NorbertoKVM_DISSERT.pdf: 2522986 bytes, checksum: 6298d49730e0d9c9d5418ad46a9b33f5 (MD5) Previous issue date: 2011-02-22 / Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior / Studies indicate that several components were isolated from medicinal plants, which have antibacterial, antifungal, antitumor and anti-inflammatory properties. Sepsis is characterized by a systemic inflammation which leads to the production of inflammatory mediators exacerbated by excessive activation of inflammatory cells and disseminated intravascular coagulation (DIC), in which the human neutrophil elastase plays an important role in its pathogenesis. Several epidemiological studies suggest that components of plants, especially legumes, can play a beneficial role in reducing the incidence of different cancers. A chymotrypsin inhibitor of Kunitz (Varela, 2010) was purified from seeds of Erythrina velutina (Mulungu) by fractionation with ammonium sulfate, affinity chromatography on Trypsin-Sepharose, Chymotrypsin-Sepharose and ion exchange chromatography on Resource Q 1 ml (GE Healthcare) in system FPLC / AKTA. The inhibitor, called EvCI, had a molecular mass of 17 kDa determined by SDS-PAGE. The purified protein was able to inhibit human neutrophil elastase (HNE), with an IC50 of 3.12 nM. The EvCI was able to inhibit both pathways of HNE release stimulated by PAF and fMLP (75.6% and 65% respectively). The inhibitor also inhibited leukocyte migration in septic mice about 87% and prolonged the time of coagulation and inhibition factor Xa. EvCI showed neither hemolytic activity nor cytotoxicity. EvCI showed a selective antiproliferative effect to HepG2 cell lines with IC50 of 0.5 micrograms per milliliter. These results suggest EvCI as a molecule antagonist of PAF / fMLP and a potential use in fighting inflammation related disorders, disseminated intravascular coagulation (DIC) and cancer / Estudos indicam que v?rios componentes medicinais foram isolados de vegetais, os quais apresentam atividades antibacterianas, antif?ngicas, antitumorais e anti-inflamat?rias. Sepse ? caracterizada por uma inflama??o sist?mica que tem como conseq??ncia a produ??o exarcebada de mediadores inflamat?rios, pela excessiva ativa??o de c?lulas inflamat?rias e coagula??o intravascular disseminada (CIVD), na qual a elastase neutrof?lica humana exerce um papel importante na sua patog?nese. Diversos estudos epidemiol?gicos sugerem que componentes de vegetais, especialmente de leguminosas, podem desempenhar um papel ben?fico na redu??o da incid?ncia de diferentes tipos de c?ncer. Um inibidor de quimotripsina do tipo Kunitz (Varela, 2010) foi purificado de sementes de Erythrina velutina (Mulungu) por fracionamento com sulfato de am?nio, cromatografias de afinidade em Tripsina-Sepharose e Quimotripsina-Sepharose e cromatografia de troca i?nica em Resource Q 1 mL (GE Healthcare), em sistema FPLC/AKTA. O inibidor, denominado EvCI, apresentou uma massa molecular de 17 kDa, determinada por SDS-PAGE. A prote?na purificada foi capaz de inibir a elastase de neutr?filos humanos (ENH), apresentando um IC50 de 3,12 nM. O EvCI foi capaz de inibir ambas as vias de libera??o de ENH estimuladas por PAF e fMLP (75,6% e 65%, respectivamente). O inibidor tamb?m inibiu a migra??o leucocit?ria em camundongos s?pticos em cerca de 87% e prolongou o tempo de coagula??o com inibi??o do fator Xa. EvCI n?o apresentou atividade hemol?tica nem citot?xica. EvCI apresentou um efeito antiproliferativo seletivo para linhagens de c?lulas HepG2 com IC50 de 0,5 &#956;g /mL. Estes resultados sugerem o EvCI como uma mol?cula antagonista dos receptores PAF/fMLP e um potencial emprego no combate a dist?rbios relacionados a inflama??o, coagula??o intravascular disseminada (CIVD) e cancer

Background e objetivo. A reconstituição celular hematopoiética com o transplante de células tronco hematopoiéticas (TCTH) alogênicas é um método de tratamento estabelecido para uma variedade de doenças hematológicas, oncológicas e imunológicas. Entretanto, TCTH está associado a considerável morbimortalidade devido a fatores como recidiva da doença de base, grau de compatibilidade HLA, tipo de regime de condicionamento e infecções durante o período de neutropenia. Este estudo investigou a associação entre o aloantígenoneutrofílico humano (HNA) e o dia de pega, a ocorrência de DECH aguda e TRM em pacientes que foram submetidos a transplante de células tronco hematopoiéticas alogênico. Tipo de estudo e local. Estudo de coorte prospectivo realizado no Hospital de Clínicas de Porto Alegre. Métodos. Avaliamos 27 pacientes transplantados entre maio de 2013 e abril de 2014 e seus respectivos doadores. A tipagem HNA foi realizada, nas amostras dos doadores, por PCR-SSP e os anticorpos anti-HNA foram detectados nos pacientes utilizando o kit LABSCREEN MULTI (LSMUTR – One Lambda). Resultados. A idade variou entre 1 a 63 anos, com uma média de 20,4 ± 17,5 anos. Dezenove pacientes eram pediátricos (<21 anos) com média de idade de 10,05 ± 6,4 anos e entre os pacientes adultos a média foi 42,2 ± 12,6 anos. Houve um discreto predomínio do sexo masculino 16 (59,3%). As leucemias agudas foram frequentes em 19 (70,4%) dos pacientes, outras doenças oncohematológicas malignas (Linfoma Hodgkin e Linfoma não Hodgkin) estiveram em 3 (11,1%) e as não malignas (síndrome mielodisplásica, osteopetrose, hemoglobinúria paroxicística noturna, aplasia e doença granulomatosa) estiveram em 6 (22,2%) dos casos. A maioria dos pacientes 19 (70,4%), apresentavam a doença há menos de 12 meses na época do transplante e 24 (88,9%) deles foram totalmente compatível com seus doadores quanto ao sistema HLA. O regime de condicionamento mieloablativo foi utilizado em 16 (59,2%) dos pacientes e a profilaxia padrão para DECH (ciclosporina e metotrexate) foi utilizada em 15 (55,5%) dos pacientes. O dia de pega teve uma mediana de 19 e mínimo e máximo de 15 e 30, respectivamente. Quatro pacientes (14,8%) tiveram óbito antes da pega. Aproximadamente 63% (17 pacientes) apresentaram DECH aguda (em todos os estágios) e a taxa de mortalidade (TRM) foi de aproximadamente 44% dos casos (12 pacientes). Os pacientes que receberam TCTH de um doador aparentado tiveram TRM de aproximadamente 41% (7 pacientes) e os que receberam de um doador não aparentado foi de aproximadamente 45% (5 pacientes). A frequência dos antígenos HNA detectados nos doadores foi de 46,4% HNA-1a, 89,3% HNA-1b, 3,6% HNA-1c, 96,4% HNA-3a, 32,1% HNA-3b, 96,4% HNA-4a, 21,4% HNA-4b, 85,7% HNA-5a e 71,4% HNA-5b. A frequência dos anticorpos anti-HNA1a, anti-HNA1b, anti-HNA1c e anti-HNA2 no D0 foram respectivamente 46,4%, 42,9%, 42,9% e 53,6%. A associação entre a tipagem HNA dos doadores e anticorpos anti-HNAdos receptores com dia da pega, DECH aguda e TRM não mostrou correlação estatisticamente significativa. Conclusão. A frequência de HNA encontradanos doadores está de acordo com o descrito pela literatura. Contudo, a frequência dos anticorpos anti-HNAs foi bastante alta na população do estudo, embora a maioria apresentasse doença há menos de 12 meses até o transplante. Apesar de não encontrarmos uma correlação, novos estudos são necessários para melhor avaliar o papel do HNA no desfecho do TCTH. / Background and purpose. Hematopoietic cellular reconstruction with allogeneic hematopoietic stem cell transplantation (HSCT) is an established method of treatment for a variety of hematological, oncologic and immunologic diseases. However, HSCT is associated with considerable morbidity and mortality due to recurrence of underlying disease, incomplete HLA compatibility, type of conditioning regimen and infection during the unavoidable period of neutropenia. This study investigates a surrogate cause of morbidity: compatibility of Human Neutrophil Antigens (HNA) between donors and receivers and its association with day of engraftment, incidence of acute graft versus host disease (GVHD) and total rate of mortality (TRM) in patients who underwent allogeneic HSCT. Type of study and location. Prospective cohort study carried out at the Hospital de Clínicas de Porto Alegre (HCPA), Brazil. Methods. We have studied 27 patients who underwent HSCT between May, 2013 and April, 2014, and their respective donors. HNA typing in the donors was performed by PCR-SSP (One Lambda) and anti-HNA antibodies in receivers were detected using the LABSCREEN MULTI kit (LSMUTR-One Lambda). Results. The age ranged from 1 to 63 years, with an average of 20.4 ± 17.5 years. Nineteen were pediatric patients (<21 years) with an average age of 10.05 ± 6.4 years, and among adult patients the average was 42.2 ± 12.6 years. There was a discreet male prevalence, 16 (59,3%). The acute leukemias were frequent in 19 (70,3%) of patients, other malignant onco-hematological diseases (Hodgkin Lymphoma and non-Hodgkin's Lymphoma) in 3 (11,1%) and non-malignant (myelodysplastic syndrome, osteopetrosis, paroxysmal nocturnal hemoglobinuria, aplasia and granulomatous disease) in 6 (22,2%). Nineteen (70,3%) of the patients, had the disease for less than 12 months at the time of the transplant and 24 (88,9%) were fully HLA compatible with their donors. Myeloablative conditioning regimen was used in 16 (59,3%) of the patients and the standard prophylaxis for GVHD (cyclosporine and methotrexate) was used in 15 (55,5%) of the patients. The day of engraftment had a median of 19 and minimum and maximum of 15 and 30, respectively. Four patients (14,8%) died before the engraftment. Approximately 17 patients (63%) showed acute GVHD (in all stages) and the total rate of mortality (TRM) was approximately 44% of the cases (12 patients). Patients who received HSCT from a related donor had TRM of approximately 41% (7 patients) and those who have received an unrelated donor was approximately 45% (5 patients). The frequency of HNA antigens detected in donors was 46,4% HNA-1a, 89,3% HNA-1b, 3,6% HNA-1c, 96,4% HNA-3a, 32,1% HNA-3b, 96,4% HNA-4a, 21,4% HNA-4b, 85,7% HNA-5a and 71,4% HNA-5b. The frequency of antibodies anti-HNA1a, anti-HNA1b, anti-HNA1c and anti-HNA2 at D0 were respectively 46,4%, 42,9%, 42,9% and 53,6%. The association between the HNA donor typing and anti-HNA antibodies of receivers with day of the engraftment, acute GVHD and TRM showed no statistically significant correlation. Conclusion. The HNA frequency found in our donors was close to the described in the literature. The frequency of anti-HNAs antibodies, however, was quite high in our study population; although the majority presented the disease for less than 12 months before the transplant. The association between HNA donor typing and anti-HNA antibodies of patients with day of engraftment, acute GVHD incidence and TRM showed no statistically significant correlation. As the number of cases was small, further studies with higher numbers and with antigen/antibodies assayed in both sides of transplantation pairs, are needed to better assess the role of the HNAs on the outcome of HSCT.